Table 5.
All-GRS | BC-GRS | IR-GRS | Lipo-GRS | B + L-GRS | |
---|---|---|---|---|---|
IGI30 | –0.031 (.44) | –0.14 (.001) | 0.039 (.43) | 0.029 (.55) | –0.063 (.19) |
M | –0.032 (.21) | 0.038 (.16) | –0.084 (.001) | 0.016 (.54) | –0.018 (.51) |
MCRI | 0.014 (.62) | 0.028 (.36) | –0.034 (.17) | –0.028 (.36) | 0.056 (.04) |
BMI | 0.0032 (.91) | –0.010 (.72) | 0.0008 (.98) | –0.076 (.007) | 0.025 (.41) |
BAI | 0.0014 (.95) | –0.011 (.65) | 0.0024 (.92) | –0.065 (.005) | 0.0069 (.78) |
Body fat | –0.0065 (.84) | –0.0099 (.77) | 0.011 (.78) | –0.080 (.02) | –0.004 (.92) |
HDL-C | –0.028 (.32) | –0.0048 (.85) | –0.055 (.07) | –0.015 (.59) | 0.053 (.06) |
Triglycerides | 0.046 (.09) | 0.013 (.64) | 0.029 (.32) | 0.022 (.42) | –0.042 (.11) |
Data are β (P value). Significant associations are highlighted in bold. Body fat and IGI30 were available only in Mexican-American Coronary Artery Disease cohort participants.
Abbreviations: B + L, body mass index plus lipids; BAI, body adiposity index; BC, beta-cell; BMI, body mass index; GRS, genetic risk score, HDL-C, high-density lipoprotein cholesterol; IGI30, insulinogenic index at 30 minutes; IR, insulin resistance; Lipo, lipodystrophy; M, glucose infusion rate; MCRI, metabolic clearance rate of insulin.